This article is more than 5 years old. Information may no longer be current.
Merck launches global registry of patients with type 2 diabetes
Click Here to Manage Email Alerts
Merck today announced plans to create a global registry that will include data on 20,000 patients with type 2 diabetes.
The registry will extract data from more than 900 sites across the United States and Europe and will include information on patients’ experiences and health outcomes over a 3-years study period.
“Type 2 diabetes is a progressive disease that affects an estimated 382 million people worldwide,” Lawrence Blonde, MD, chair of the Merck type 2 diabetes registry, and director of the Ochsner Diabetes Clinical Research Unit at the Ochsner Medical Center, New Orleans, said in a press release from Merck. “By evaluating a full range of data, the Merck registry will provide valuable insights into opportunities to improve the care of people with type 2 diabetes on both regional and global levels.”
The registry is to include “comprehensive, real-world data” from sources including surveys and, for United States patients, administrative claims data. The registry aims to detect gaps in type 2 diabetes management and new data trends that could help in designing future type 2 diabetes treatment methods.
For more information: Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes